Short Interest in Bruker Corporation (NASDAQ:BRKR) Declines By 16.1%

Bruker Corporation (NASDAQ:BRKR) was the recipient of a large drop in short interest in December. As of December 15th, there was short interest totaling 11,497,888 shares, a drop of 16.1% from the November 30th total of 13,704,909 shares. Based on an average daily volume of 2,221,732 shares, the short-interest ratio is currently 5.2 days. Approximately 10.4% of the shares of the stock are short sold. Approximately 10.4% of the shares of the stock are short sold. Based on an average daily volume of 2,221,732 shares, the short-interest ratio is currently 5.2 days.

Insiders Place Their Bets

In other Bruker news, Director John A. Ornell sold 6,233 shares of Bruker stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total value of $243,087.00. Following the completion of the transaction, the director owned 35,212 shares in the company, valued at approximately $1,373,268. The trade was a 15.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 27.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Bruker

A number of institutional investors have recently made changes to their positions in BRKR. Orbis Allan Gray Ltd bought a new stake in Bruker in the second quarter valued at about $192,735,000. AQR Capital Management LLC increased its stake in shares of Bruker by 125.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after acquiring an additional 1,850,215 shares during the last quarter. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Bruker in the 2nd quarter valued at about $62,032,000. Norges Bank acquired a new stake in shares of Bruker in the 2nd quarter valued at approximately $44,459,000. Finally, UBS Group AG boosted its stake in Bruker by 196.4% during the 3rd quarter. UBS Group AG now owns 1,413,919 shares of the medical research company’s stock worth $45,938,000 after acquiring an additional 936,820 shares during the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Price Performance

Shares of BRKR stock opened at $47.51 on Wednesday. The firm has a market cap of $7.22 billion, a price-to-earnings ratio of -296.94, a PEG ratio of 7.13 and a beta of 1.17. Bruker has a 12 month low of $28.53 and a 12 month high of $64.64. The company has a quick ratio of 0.91, a current ratio of 1.85 and a debt-to-equity ratio of 0.81. The stock has a 50-day moving average price of $44.18 and a 200 day moving average price of $39.06.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.33 by $0.12. The company had revenue of $860.50 million during the quarter, compared to analysts’ expectations of $847.40 million. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. Bruker’s revenue was down .5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.60 EPS. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. Research analysts expect that Bruker will post 2.69 EPS for the current year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 2nd. Shareholders of record on Monday, December 8th will be given a dividend of $0.05 per share. The ex-dividend date is Monday, December 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Bruker’s payout ratio is presently -125.00%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on BRKR. Rothschild & Co Redburn initiated coverage on Bruker in a research note on Thursday, November 20th. They issued a “buy” rating and a $60.00 target price for the company. Zacks Research raised shares of Bruker from a “strong sell” rating to a “hold” rating in a report on Monday, December 8th. Redburn Partners set a $60.00 price objective on shares of Bruker in a research report on Thursday, November 20th. Bank of America boosted their target price on shares of Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Finally, UBS Group upped their target price on shares of Bruker from $40.00 to $43.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Bruker presently has an average rating of “Hold” and a consensus price target of $51.38.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.